Why is the Burberry share price up 20% so far this year?

Shares in Burberry Group plc (LON:BRBY) are riding high as the luxury fashion house makes good progress on its turnaround.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2018 is shaping up to be another good year for fashion firm Burberry (LSE: BRBY). The company’s share price is riding high as the luxury fashion house makes good progress on its turnaround.


Under Marco Gobbetti’s leadership, Burberry is going through a wide-ranging overhaul as it seeks to improve its financial performance.

Gobbetti, who replaced Christopher Bailey as the company’s chief executive last year, has brought with him more than 20 years of experience in the luxury goods industry. He has a proven track record of developing and executing effective operating and growth strategies, and had most recently overseen robust double-digit sales growth atLVMH’s Céline.

His most important move at the Burberry so far, was to move the brand even further upmarket. As part of the company’s new strategy, Burberry is aiming for a more exclusive positioning, as it seeks to deliver a more complete wardrobe offer for affluent consumers who want a distinctive British look.

Meanwhile, the company has stepped up cost cuts and an efficiency drive, and is on track to deliver cumulative savings of £100m by the end of this year. In another major development, Burberry has partnered with online marketplace Farfetch as it seeks to expand the brand’s distribution globally and further strengthen its e-commerce presence.

Flat sales

These big changes have yet to deliver a significant improvement on its top-line performance, however. Retail sales were broadly flat in the 13 weeks to June 30, as growth in Asia Pacific and the Americas was offset by weaker tourism demand in the UK and Europe.

And due to big investments needed to reposition the brand further upmarket, its bottom-line is forecast to dip slightly in the near term. City analysts currently expect underlying earnings to drop 4% in 2018/19, before making a 6% recovery in 2019/20.

Encouraging progress

Elsewhere, generic drugs maker Hikma Pharmaceuticals (LSE: HIK) is another stock to watch out for. Shares in the company have gained more than 40% since the start of the year, following recent successful product launches and encouraging progress to grow sales by enhancing and investing in its pipeline of new drugs.

Although core operating profit dipped 8% to $386m in the last financial year, amid increased competition for some of its injectable medicines in the US, the company’s branded drugs division continues to show resilience. Profitability in its branded business had remained stable, with core operating profits of $114m.

Fast-growing markets

Looking ahead, City analysts expects resilient demand for its branded portfolio of drugs, together with recent product launches, will drive sales growth over the next few years. Longer term, Hikma’s exposure to fast-growing markets in the Middle East and North Africa and its focus on affordable medicines puts it in a strong position to benefit from long-term sustainable growth in the health sector.

But it’s not just on the top line that the company hopes to deliver improvement — it’s also taking aim at its high cost base. Initiatives to improve operational efficiency are being rapidly implemented, as it seeks to defend margins from pricing pressure.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any of the shares mentioned. The Motley Fool UK has recommended Burberry and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

7%+ dividend yields! Here are 2 of the best UK shares to consider buying in June

This Fool has been searching for UK shares with the best dividend yields. Here are two he thinks investors should…

Read more »

Investing Articles

5 FTSE 100 shares to consider buying for passive income right now

The FTSE 100 is having its best start to the year for ages, and that's pushing the top dividend yields…

Read more »

Investing Articles

One overlooked cheap share to tap into the year’s hottest theme?

This Fool describes the key things to think about when investing in copper stocks and analyses one cheap share to…

Read more »

Investing Articles

A cheap FTSE 100 stock that’s ready for a dividend hike in 2024

This banking giant is one of the FTSE 100's greatest dividend stocks. And at current prices, our writer Royston Wild…

Read more »

Growth Shares

Is the BP share price set to soar after Michael Burry invests in the firm?

Jon Smith takes note of a recent purchase from the famous investor behind The Big Short and explains his view…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

I’d focus on Kingfisher now after the Q1 report leaves the share price unmoved

With the share price near 262p, is the FTSE 100’s Kingfisher a decent investment now for dividends and business recovery?

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

£500 buys me 493 shares in this 7.4% yielding dividend stock!

The renewable energy sector remains out of favour. As a result, there are some high-yielders around, including this dividend stock.

Read more »

Road trip. Father and son travelling together by car
Investing Articles

If I’d put £10k into Tesla stock 2 years ago, here’s what I’d have now

Tesla stock has fallen in the past few years. But the valuation looks temptingly low now, as we approach a…

Read more »